{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:58:05Z","timestamp":1790611085179,"version":"4.1.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"abstract":"<jats:p>This Viewpoint discusses most-favored-nation drug pricing and how to strengthen this type of drug pricing in Medicare.<\/jats:p>","DOI":"10.1001\/jamainternmed.2026.4520","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:30:32Z","timestamp":1790609432000},"source":"Crossref","is-referenced-by-count":0,"title":["Policy and Design Considerations for Most-Favored-Nation Drug Pricing"],"prefix":"10.1001","author":[{"given":"Matthew","family":"Vogel","sequence":"first","affiliation":[{"name":"John F. Kennedy School of Government, Harvard University, Cambridge, Massachusetts"},{"name":"Now with Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier J.","family":"Wouters","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"18","key":"ivp260024r4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.2026.3536","article-title":"International reference pricing across Medicare and Medicaid: evaluating CMS models.","volume":"335","author":"Kang","year":"2026","journal-title":"JAMA"},{"issue":"18","key":"ivp260024r5","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1056\/NEJMp2518292","article-title":"Medicaid\u2019s GENEROUS most-favored-nation pricing model: promise and limitations.","volume":"394","author":"Maini","year":"2026","journal-title":"N Engl J Med"},{"issue":"18","key":"ivp260024r6","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1056\/NEJMp2600417","article-title":"Reforming payment for clinician-administered drugs: most-favored-nation pricing in Medicare part B.","volume":"394","author":"Hwang","year":"2026","journal-title":"N Engl J Med"},{"issue":"10","key":"ivp260024r10","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1377\/hlthaff.2024.00089","article-title":"Low- and middle-income countries experienced delays accessing new essential medicines, 1982-2024.","volume":"43","author":"Wouters","year":"2024","journal-title":"Health Aff (Millwood)"},{"key":"ivp260024r1","doi-asserted-by":"crossref","unstructured":"Mulcahy? AW, Schwam? D, Lovejoy? SL. International prescription drug price comparisons: estimates using 2022 data. RAND Corporation. Published February 1, 2024. Accessed May 17, 2026 May 17. https:\/\/www.rand.org\/pubs\/research_reports\/RRA788-3.html","DOI":"10.7249\/rhq-11-03-05"},{"key":"ivp260024r2","unstructured":"Kearney? A, Montalvo? J? III, Kirzinger? A, Hamel? L. Public opinion on prescription drugs and their prices. KFF. Published March 31, 2026. Accessed July 21, 2026. https:\/\/www.kff.org\/health-costs\/public-opinion-on-prescription-drugs-and-their-prices\/"},{"key":"ivp260024r3","unstructured":"Savings from most-favored-nation (MFN) drug pricing policy. The White House. Published May 2026. Accessed May 5, 2026. https:\/\/www.whitehouse.gov\/research\/2026\/05\/savings-from-most-favored-nation-drug-pricing-policy\/"},{"key":"ivp260024r7","unstructured":"Centers for Medicare & Medicaid Services. GLOBE (Global Benchmark for Efficient Drug Pricing) model. Updated December 29, 2025. Accessed May 23, 2026. https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/globe"},{"key":"ivp260024r8","unstructured":"Centers for Medicare & Medicaid Services. GUARD (Guarding U.S. Medicare Against Rising Drug Costs) model. Updated December 29, 2025. Accessed May 23, 2026. https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/guard"},{"key":"ivp260024r9","unstructured":"Vogel? M, Rangaraj? S, Wouters? OJ. The Trump administration\u2019s deals with pharma: policy progress or political theater? Health Affairs Forefront. Published July 30, 2026. Accessed August 25, 2026. https:\/\/www.healthaffairs.org\/content\/forefront\/trump-administration-s-deals-pharma-policy-progress-political-theater"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2854600\/jamainternal_vogel_2026_vp_260024_1790087525.88743.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:30:35Z","timestamp":1790609435000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2854600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":10,"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2026.4520","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,28]]}}}